ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's clarified a news report regarding Thailand's approval of its antibiotic NULZOLVENCE. The company confirmed the reports are correct and based on a joint press release.
Dr. Reddy's Laboratories clarified that recent trading volume increases are not driven by undisclosed material events. The company separately confirmed it received Drug Identification Numbers from Health Canada for its Semaglutide Injection on April 22, 2026, though final 'Notice of Compliance' approval is still pending.
Dr. Reddy's clarified a news report regarding its Semaglutide Injection. The company confirmed it is awaiting 'Notice of Compliance' from Health Canada but has received 'Drug Identification Numbers' as of April 22, 2026. Management stated there is no material impact on the company from the news article.
Dr. Reddy's Laboratories clarified a news report regarding its Semaglutide Injection. The company confirmed it has not yet received a 'Notice of Compliance' from Health Canada but did receive 'Drug Identification Numbers' (DINs) on April 22, 2026. The company continues to engage with regulatory authorities for Canadian market approval.
Dr. Reddy's Laboratories clarified news reports regarding its Semaglutide Injection. The company confirmed it is still awaiting 'Notice of Compliance' from Health Canada, though it received Drug Identification Numbers on April 22, 2026. Management remains engaged with regulatory authorities to bring the product to the Canadian market.